Vicki Sato will join Vertex Pharmaceuticals Inc. of Cambridge,Mass., as vice president, chief scientific officer and chairmanof the scientific advisory board. Sato had been vice presidentfor research at Biogen Inc.
Somatix Therapy Corp. of Alameda, Calif., appointed Ronald J.Mandel as section head for in vivo models in the company'sneural diseases program. Mandel was an assistant professor atthe University of Illinois.
Deprenyl Research Ltd. of Toronto appointed Sen. StanleyHaidasz and Martin Siegerman directors of corporatedevelopment.Siegerman, who is retired, was chairman of RoyalBank Investment Management Inc.
Immulogic Pharmaceutical Corp. of Cambridge, Mass., promotedMalcolm Morville to vice president of the new AllergicDiseases Strategic Business Unit. Julia Greenstein waspromoted to vice president of the Autoimmune DiseasesResearch Group.
Keith Mansford has joined the board of directors of GenelabsTechnologies Inc. of Redwood City, Calif. Mansford waschairman of the biopharmaceutical division of Howard FischerAssociates in Philadelphia.
Advanced Tissue Sciences Inc. of La Jolla, Calif., appointedWilliam Tolbert as vice president, process development.Tolbert had been vice president of technical affairs forCentocor.
Cytel Corp. of San Diego, Calif., appointed Richard M. Rose vicepresident, medical affairs and chief medical officer. Rose wasthe director of the division of pulmonary and critical caremedicine at New England Deaconess Hospital and associateprofessor of medicine at Harvard Medical School.
Biocyte Corp. of New York, N.Y., appointed Betty Curry Johnsonto vice president of operations and David A. Feinberg to vicepresident of marketing and sales. Johnson was senior projectmanager for the pharmaceutical division of Miles Inc. Feinbergwas executive director of marketing licensing and acquisitionfor Ciba Consumer Pharmaceuticals.
NPS Pharmaceuticals Inc. of Salt Lake City named Doug Reed toits board of directors. He is vice president of S.R. One Ltd.
EcoScience Corp. of Worcester, Mass., named Michael D. Andismanager of product development and Kenneth K. Kuhajdaeastern regional sales manager. Andis was manager ofbiological research and product development at Roussel BioCorp. Kuhajda was northeast sales representative for Roussel.
Applied Immune Sciences Inc. of Menlo Park, Calif., named K.Frank Austen to its board of directors. He is a Harvard MedicalSchool professor and chairman of the department ofrheumatology and immunology at The Brigham and Women'sHospital.
Lowell T. Harmison, former deputy assistant secretary forhealth of the U.S. public health service, was appointed to theboard of directors at Biomira Inc. of Edmonton, Alberta.
Hubert M. Quinn was promoted to vice president of chemicalproduction from manager of chemical production at PerSeptiveBiosystems Inc. of Cambridge, Mass.
Biogen Inc. of Cambridge, Mass., named Ian Hirst director ofmanufacturing. He was director of process development atSmithKline Beecham.
Celtrix Pharmaceuticals of Santa Clara, Calif., appointed J.Michael Delmage director of its ophthalmic program. He was asenior program manager at Chiron Ophthalmics.
Therapeutic Antibodies Inc. of Nashville, Tenn., named John S.Cipriano vice president of regulatory affairs and compliance.He was deputy director of the Division of BiologicalInvestigational New Drugs at the Office of Biologics of theFDA.
Kenneth W. Narducy was named president of Oculex Inc. ofMountain View, Calif. He was vice president of research anddevelopment at CooperVision.
Advance Tissue Sciences Inc. of La Jolla, Calif., appointedWilliam Tolbert vice president of process development. He wasvice president of technical affairs for Centocor Inc.
Genelabs Technologies Inc. of Redwood City, Calif., namedKeith Mansford to its board of directors. He was chairman ofresearch and development for SmithKline Beecham plc.
Paracelsian Inc of Ithaca, N.Y., named Kelvin W. Welbourne vicepresident of operations. He was with Coors Biotechnology, asubsidiary of the Adolph Coors Co.
(c) 1997 American Health Consultants. All rights reserved.